

SBUR NEWSLETTER

SUMMER 2026

A MESSAGE FROM THE PRESIDENT



Travis J. Jerde, PhD
SBUR President

Dear SBUR Members and Colleagues:

I grant you all a very warm greeting this summer. Well, for most of us in the middle of the USA this summer, it must be a warm greeting with the weather we've been having! I sure hope everyone has enjoyed their summer and is staying safe and COOL!

There is so much going on with your society, it gets hard to track sometimes. Please use this Newsletter as a primer and an informational, a summary of our recent activities, and a look forward to the fall. Starting this year, your SBUR newsletter will be coming twice per year, once in the Summer, and once before the new year in early winter. This approach allows us to highlight the busy spring and fall schedules more succinctly and timely.

Let's talk about our Spring! Attending the SBUR at AUA this spring was a great rewarding experience. Dr. Yu will highlight this in more detail later in this edition but just let me say a few things from the President's perspective. First, the cooperation between the Society for Urological Oncology (SUO) and SBUR continues to bring very fruitful meetings focused on the basic biology and translational twist of urological cancers. It was especially warming to see Dr. Yu introduce her esteemed mentor, Dr. Arul Chinnaiyan, as the 2026 Don Coffey Lecturer. An outstanding

talk, and an outstanding experience. Additionally, this was the first year of our collaboration with the AUA office of research for the joint AUA-SBUR research symposium focusing on the basic biology of benign urological disease. This collaboration with the AUA office allowed us to expand our footprint at the meeting and include an expanded discussion time with our audience and expert panelists who led a great discussion. We look forward to next year's edition. Finally, spring was especially rewarding for me, because I got to see my friend and colleague Dr. Rosalyn Adam receive, in person, the SBUR-Society of Women In Urology distinguished research award. There is no more deserving winner. It was such a great experience to see this in a large room filled with distinguished women working in urological research, basic and clinical, long-standing researchers and those just getting started. Be sure and read Dr. Hadjifrangiskou's article below, honoring Dr. Adam.

I'm truly enjoying the summer research discussions being led by our Past President, Dr. Chris Jamieson. These are half-hour discussions with some of our best trainees in our society, across a swath of research areas. Make sure you tune into these as your schedule permits.

I'm very much looking forward to our fall meeting in Memphis this November. I love the venue and city of Memphis—and it's a new venue for us. I love the culture of the city, the music, the food, and the vibe. With Beale Street in our background, there will be lots of places to eat and have engaging conversations with colleagues inside, and outside, of the meeting walls. Dr. Strand and his committee have put together a truly outstanding program with some of our society's best research. A key point this year and going forward will be our focus on broadening our areas of research presented and displaying great work across the areas of urology. As always, the cutting edge of urological basic research will be on display at our large poster sessions filled with the greatest up and coming minds in the field, and eager and ready to chat with colleagues and new collaborators. Have a look at the agenda and book your trip to Memphis today!

Behind the scenes, we'll be working on building our research advocacy efforts, with AUA, APS, and others, expanding our collaborative efforts around the globe, and continuing our recently expanded fundraising and sponsorship efforts. We have far more sponsorship than ever before, due to the work of our committees and our management group at Veritas. The Society is in strong shape because of all of you—our members. We are so grateful for all your efforts!

The SBUR elections have wrapped up. I hope you were able to vote. During these difficult research times, having a strong society in basic urological research working with you can be critical. Take part in your organization and let's build the future of basic urological research.

Best regards,



EXECUTIVE COMMITTEE 2025-2026



Travis Jerde, PhD
President



Jindan Yu, MD
Vice President



Christina Jamieson, PhD
Immediate-Past President



Maria Hadjifrangiskou, PhD
Secretary




Xin Lu, PhD
Treasurer



Timothy L. Ratliff, PhD
Emeritus Member



Nate Brennen, PhD
Director At-Large



Tanya Stoyanova, PhD
Director At-Large



Li Xin, PhD
Director At-Large

SBUR 2026 ELECTIONS UPDATE

Votes are in and the results are being tallied.

The SBUR Executive Committee has four open leadership positions. The nominees for each position are the following:

PRESIDENT-ELECT

- Dr. Benyi Li – University of Kansas Medical Center
- Dr. Douglas Strand – UT Southwestern Medical Center

TREASURER-ELECT

- Dr. Xiaoqu Liu – University of Kentucky
- Dr. Ping Mu – Yale University

DIRECTORS-AT-LARGE (TWO POSITIONS AVAILABLE)

- Dr. Goutam Chakaborty – Mount Sinai
- Dr. Laura Pascal – University of Pittsburgh
- Dr. Renee Vickman – Endeavor Health
- Dr. Anna Woloszynska – Roswell Park Comprehensive Cancer Center

RESULTS WILL BE ANNOUNCED AT THE ANNUAL MEETING IN NOVEMBER.

ANNUAL MEETING INFORMATION

The SBUR Annual meeting will be taking place Thursday, November 12 – Sunday, November 15 at the Memphis Riverline hotel by Marriott (formally the Sheraton Downtown Memphis) in beautiful downtown Memphis Tennessee.

The meeting starts with the preconference Trainee Affairs program being led by co-Chairs, Steve Kregal, PhD and Simpa Salami, MD. This two-hour session with feature topics which will include writing a competitive research grant proposal and funding opportunities in Urologic research. Plan accordingly to attend this session.

The general session kicks off with the AUA Lectureship featuring Noma Sharifi, MD. The evening concludes with a welcome reception where you can network with colleagues or catch up with friends.

Friday features a variety of Plenary session with topics on rising star in urology, mechanisms of urinary tract infection and development and developmental diseases of the urogenital tract. Also plan to attend the industry lunch presentation sponsored by Merck. The day will conclude with the first scientific poster session.

Saturday begins with the highly anticipated Leland W.K. Chung Lecture, given by Massimo Loda, MD titled "The Fat Side of Prostate Cancer: Targeting Lipid Metabolism." Two plenary sessions will then focus on molecular targeting of primary urogenital tumors and immunotherapy in urogenital disorders. The day will also feature trainee presentations, the SBUR Awards Ceremony, and the SBUR Business Meeting, ending with a second scientific poster session.

On Sunday, the Dr. Lealand W.K. Chung Mentorship Award will be presented, followed by a plenary session on novel model systems in urology.

Registration is open. To see the full agenda and other details, or to register, please visit the SBUR website at <https://sbur.org/>. Looking forward to seeing you in November.

REGISTER NOW!



SPRING MEETING RE-CAP



Dr. Jindan Yu, MD
SBUR Vice President

I would like to thank our members who attended the 2026 AUA Annual Meeting and the SBUR Spring Meeting in Washington, DC, this May. I am especially grateful to everyone who accepted our invitation and traveled to speak, moderate, or participate in the two SBUR scientific programs. The inaugural AUA/SBUR Joint Research Symposium featured 17 scientific presentations and 12 clinician panelists across three sessions, while the SBUR-SUO Joint Scientific Session included 8 scientific presentations, 9 translational discussants, and the Donald S. Coffey Lecture. Both programs attracted strong attendance and stimulated engaging, lively discussions while providing an important platform to highlight SBUR, its members, and the breadth of their research to the larger AUA membership and Annual Meeting audience.

On Friday, May 15, the inaugural AUA/SBUR Joint Research Symposium was held from 7:30–11:30 a.m. and 1:00–3:00 p.m. This new full-day program replaced the SBUR afternoon breakout session on benign urology held in previous years. Co-chaired by AUA representative Kristina Penniston and me as the SBUR representative, the symposium brought together basic scientists, translational investigators, and clinicians for

three sessions addressing comorbidity-induced genitourinary problems, emerging mechanisms of benign prostatic hyperplasia, and urothelial pathophysiology in functional bladder disorders. Topics ranged from neurological disease, diabetes, aging, circadian disruption, and radiation injury to stromal biology, metabolism, hormonal regulation, environmental exposures, inflammation, and tissue repair.

We were also delighted to resume the SBUR International Scholar Program following its pause during the COVID-19 pandemic. Zhiping Wang of Lanzhou University participated as the 2026 SBUR International Scholar and presented his research on physical therapy and the local microenvironment of chronic prostatitis. The renewed program strengthens SBUR's international engagement and creates valuable opportunities for scientific exchange and future collaborations.

A major innovation in the inaugural AUA/SBUR symposium was the addition of “Lab Meets Practice: Clinician-Scientist Discourse” panel discussions. Each scientific session concluded with a moderated conversation involving clinician panelists, allowing speakers and practicing urologists to examine how laboratory discoveries relate to unmet clinical needs, the limitations of current disease models, and potential paths toward translation. This format created a productive bridge between mechanistic research and clinical practice.



On Saturday, May 16, the SBUR–SUO Joint Scientific Session on urologic oncology was held from 8:00 a.m. to noon, featuring a strong program co-developed by Sam Chang (representing SUO) and me (SBUR), with valuable contributions from Debasish “Deb” Sundi (SUO). Moderated by Debasish “Deb” Sundi and me, the session highlighted emerging discoveries in bladder, kidney, and prostate cancers. Presentations addressed DNA-damage memory and tumor evolution, molecular residual disease, sex-dependent selection pressures, extracellular-vesicle RNA biomarkers, TRAIL signaling in VHL-deficient renal cell carcinoma, and mechanisms of therapy resistance and lineage plasticity in advanced prostate cancer. This year's session also included translational discussants for each disease-focused section. These experts placed the scientific presentations within a clinical context and stimulated thoughtful discussion about how emerging biomarkers, disease classifications, and therapeutic vulnerabilities might be advanced toward patient care.

A particularly memorable highlight was the 2026 Donald S. Coffey Lecture, delivered by Arul Chinnaiyan, recipient of this year's Donald S. Coffey Award. Dr. Chinnaiyan reviewed several of his landmark discoveries, including recurrent gene fusions in prostate cancer and the roles of SWI/SNF chromatin-remodeling complexes and FOXA1 gene alterations in tumor progression. He then presented exciting recent research on AR-p300/CBP DALTACs as a novel strategy for disrupting oncogenic transcriptional programs in AR-positive prostate cancer. His lecture generated tremendous interest and excitement among the audience and exemplified the innovative and interdisciplinary spirit of Dr. Coffey's scientific legacy.

Finally, I would like to thank Zhou Wang for his advice and contributions to organizing the inaugural AUA/SBUR Joint Research Symposium. I am also grateful to our President, Travis Jerde; Past President, Christina Jamieson; and the entire SBUR Executive Committee for their valuable guidance and support in planning this spring's programs. My sincere thanks also go to our management team, Marty Roth and Tammy Borden, for their dedicated assistance. Finally,

I am deeply grateful to the AUA Research Council; Johanny Kugelman-Tonos; Marielle Marktanner; Angela Kinnunen; and the entire AUA team for their outstanding partnership and collaboration in making these programs possible.

We look forward to seeing everyone at next year's SBUR Spring Meeting, held in conjunction with the AUA Annual Meeting, May 21–24, 2027, at the San Diego Convention Center in San Diego, California.



2026 SWIU/SBUR AWARD FOR EXCELLENCE IN UROLOGICAL RESEARCH



Rosalyn M. Adam, PhD

It is my distinct honor and pleasure to highlight the scientist awarded the 2026 SWIU/SBUR award for excellence in urological research, Dr. Rosalyn Adam. She has made a tremendous impact in the field of basic urologic research, while at the same time serving as an impeccable role model to trainees and colleagues alike. I remember meeting Dr. Adam for the first time at my first ever SBUR annual meeting in 2015, where I felt so nervous – as an assistant professor new to the Society – to meet someone like her who made so many contributions to the field of basic science in bladder biology and pathology. I remember Dr. Adam being open and kind and very engaging, making me feel at ease in a new conference environment. Dr. Adam is a giant in the field. Trained as a Cell Biologist at the University of Southampton, where she received her PhD, and later at Boston Children's Hospital, where she completed post-doctoral studies, Dr. Adam established a rigorous research program that seeks to dissect the mechanisms that underlie different types of bladder dysfunction. Through her scientific journey, she has made contributions towards understanding the signal transduction perturbations that may be associated with bladder conditions, including bladder obstruction, interstitial cystitis, neurogenic bladder and bladder pain syndrome. Dr. Adam's approaches are inter-disciplinary and evolve at the pace of advancing technology. A notable endeavor in Dr. Adam's laboratory is the development of novel assay that uses "precision-cut bladder slices to enable measurement of physiologically relevant endpoints in mouse and human bladder tissue such as contraction, relaxation and stiffness while keeping the native tissue microenvironment intact". A recent

article from her lab, which exemplifies her approach to science in my opinion can be found [here](#), providing key insights into how the molecular landscape of the bladder changes after spinal cord injury, and showcasing how Dr. Adam's group integrates omics approaches to advance bladder research. Dr. Adam has published in at least 150 original articles and reviews, which are highly cited. In terms of leadership, Dr. Adam serves as Director of Basic Urological Research and holds the David E. Retik Chair in Urology at Boston Children's Hospital. As faculty at Harvard Medical School, she oversees a team of graduate students, fellows and staff scientists and has mentored numerous individuals. In the broader urologic community, Dr. Adam has served on the SBUR board, including serving as President for 2019-2020. Dr. Adam is tremendously respected by colleagues and mentees alike. A quote from Dr. Kyprianou: "Rosalyn brought steady leadership to the SBUR, with charisma and wisdom, inspiring the younger generation of female scientists within the space of Urology to pursue their research and academic goals with grace, quite strength and courage". Dr. Lam, Chair of SBUR's Awards Committee states: "Dr. Rosalyn Adam's contributions extend beyond her seminal discoveries in cellular signaling and tissue remodeling in bladder physiology and cancer; she is equally recognized for her exceptional mentorship and unwavering dedication to advancing the field of urologic research."

Dr. Adam, thank you for your contributions to basic urologic research, your leadership and mentorship!

Maria Hadjifrangiskou

Maria Hadjifrangiskou, PhD
SBUR Secretary

2025 ANNUAL MEETING TRAVEL AWARDEES

How is it already time for the NEXT Fall meeting?! What a better way to drum up excitement than to highlight the wonderful talent that participated in last year's forum? We invited the early-career awardees to respond to two questions: to describe their presentation or poster and to share how attending the meeting has contributed to their career development. Here are the winners and their responses:



Justine Jacobi, PhD, Roswell Park Comprehensive Cancer Center, Travel Awardee, selected for podium presentation

Our work investigated how loss of the histone methyltransferase, EZH2, influences prostate cancer variant evolution. Using genetically engineered mouse models, we found that EZH2 is not required for progression to aggressive disease states, including neuroendocrine and double-negative prostate cancer, but instead drives distinct epigenetic and transcriptional programs that shape lineage dynamics.

I am incredibly grateful to have received the SBUR Trainee Travel Award, which gave me the opportunity to present our findings not only during the poster session, but also as a podium talk where I received exceptional feedback and opened the door to new collaborative opportunities. As an early-career scientist hoping to become an independent researcher, opportunities like this are extremely valuable, and the intimate setting of the SBUR meeting makes these interactions especially meaningful.



Jagpreet Singh Nanda, PhD, Cedars-Sinai Medical Center, Travel Awardee

I presented my research at the SBUR 2025 meeting in Orlando, Florida, where I showcased findings demonstrating that the transcription factor ONECUT2 functions as a metabolic master regulator promoting tumor growth, inhibiting apoptosis, and mediating epigenetic modifications. These results further suggest that ONECUT2 inhibition may represent a viable therapeutic strategy to disrupt metabolic networks driving metastatic, treatment-resistant prostate cancer. In recognition of this work, I was awarded the SBUR Travel Award. This honor reflects the scientific merit and potential impact of the study while further motivating my continued commitment to translational cancer research.

The meeting provides a valuable academic forum for scientific exchange, mentorship, and collaboration with leaders in urology. Notably, discussions initiated during the conference have resulted in a significant new collaboration that will advance my ongoing research efforts. The SBUR meeting continues to serve as an essential platform for trainee development, scholarly engagement, and professional growth.



John Phoenix, Loyola University, Travel Awardee

Despite initial effectiveness, standard-of-care prostate cancer therapies targeting androgen receptor (AR) often fail via selective bypass of AR signaling, or via shift toward aggressive and sometimes AR-indifferent disease phenotypes, known collectively as aggressive variant prostate cancer (AVPC). Our latest work shown at SBUR uncovered a direct physical interaction between the transcription factors SOX2 (famous cellular reprogramming factor) and FOXA1 (AR co-regulator and potent oncogene) with meaningful downstream implications in the most aggressive and lethal forms of prostate cancer, which we hope can serve as the knowledge basis for new ways to treat prostate cancer and help patients.

The SBUR Travel Award supported my career development in several ways, namely by increasing my work's visibility and affording me the invaluable opportunity to meet with leaders in the field of urologic oncology to discuss research and foster new professional connections and collaborations. I'm very grateful to SBUR for their support and look forward to remaining involved.




Md. Niaz Morshed, Louisiana State University Health Sciences Center, Travel Awardee

My poster highlighted how DGAT1-driven lipid droplet formation in cancer-associated fibroblasts promotes extracellular matrix remodeling and pro-tumorigenic signaling in prostate cancer, identifying stromal lipid metabolism as a promising therapeutic target.

Receiving the SBUR Travel Award allowed me to share this work with leaders in urologic research, gain valuable feedback to strengthen its translational impact, and further solidify my goal of pursuing an academic career focused on targeting stromal metabolism in the tumor microenvironment in advanced prostate cancer.

2025 ANNUAL MEETING TRAVEL AWARDEES



Chuan Yu, PhD, University of California Santa Cruz, Eula and Donald S. Coffey Innovative Research Award finalist

My presentation at SBUR introduced a novel autochthonous, locally initiated mouse bladder cancer model that integrates lineage tracing with electroporation-mediated CRISPR/Cas9 genome editing to investigate the cells of origin in bladder cancer. By combining lineage tracing with single-cell RNA sequencing, we demonstrate that basal urothelial cells give rise to a broader spectrum of tumor subtypes and exhibit greater tumorigenic potential and aggressiveness than luminal cells, highlighting the critical role of cell of origin in shaping bladder cancer heterogeneity at both histological and molecular levels.

As a first-time attendee at the SBUR Fall Meeting, receiving this Travel Award has been highly valuable for both my research and career development. It enabled me to share my work with leading investigators and colleagues in urology, receive constructive feedback, and expand my professional network.



Jordan Velky, PhD, University of Illinois Chicago, Travel Awardee, selected for podium presentation

Metabolic reprogramming occurs in response to GLP1R agonist exposure (e.g. semaglutide, brand name Ozempic) and is also a hallmark of prostate cancer disease progression. Recently, our lab and others have identified the expression of GLP1R in advanced prostate cancer, supporting a model whereby systemic GLP1R agonism can affect prostate cancer signaling and progression by directly binding to prostatic GLP1R. Understanding the effects of GLP1R expression and signaling in prostate cancer cells could provide an additional context where GLP1R agonism is therapeutically valuable.

I have been attending SBUR since 2015. The research community is exceptionally supportive and collaborative, making it an outstanding conference for trainees and early-career investigators. Presenting my work after receiving the SBUR Travel Award last year generated numerous new ideas and fostered valuable collaborative opportunities, significantly advancing my project through the support of the SBUR research community.



Hongshun Shi, MD, PhD, Emory University, Eula and Donald S. Coffey Innovative Research Award finalist

Combining scRNA-seq with a spatial framework of gene expression analyses of transgenic mouse models, we demonstrated a critical role of CXCR7 in remodeling the tumor microenvironment of prostate cancer through interferon gamma signaling.

It's a great honor to attend the meeting and present our work in this great platform. We received constructive feedback in the meeting and I also learned a lot from others in the research area. It's really a great opportunity for growth in the scientific research career.



Lucy Kisova, Cornell University, Travel Awardee

In my research, I aim to determine how the chromatin remodeler CHD7 helps drive and maintain the neuroendocrine prostate cancer phenotype as epigenetic reprogramming is an important component of lineage plasticity. My poster focused on biological functions regulated from CHD7 overexpression via CRISPR activation in androgen-dependent cell lines.

As a Master's student who has been in my lab for a year now, the SBUR meeting was my first real opportunity to showcase my work to an audience of professionals in the field and connect with professors and trainees from outside my institution. Sharing my research in this environment helped me grow my network while building public speaking skills and confidence required for scientific communication throughout my career, including my thesis defense this month.



Umar Mehraj, PhD, Duke University, Travel Awardee

Our work demonstrates that spindle assembly checkpoint (SAC) and G2/M signaling programs represent critical vulnerabilities in aggressive, AR-indifferent prostate cancer, implicating defects in cell cycle regulation. Within these pathways, TTK kinase is identified as a key dependency and a potential therapeutic target.

The SBUR Travel Award provided an invaluable opportunity to share these findings with leaders in urologic oncology and build collaborations that advance my goal of developing new therapies for advanced prostate cancer.

2025 ANNUAL MEETING TRAVEL AWARDEES



Varshiny Gopinath, Indian Institute of Technology Madras & University of California San Diego, Travel Awardee, selected for podium presentation

I delivered an oral presentation focused on establishing urethral stricture organoids derived from patients with challenging disease recurrence, making this the first-of-its-kind translational model for urethral stricture disease. These organoids closely mimic the patient's own disease biology, providing a powerful platform to study disease pathogenesis and identify key mechanistic pathways driving fibrosis and stricture formation. Along with, I presented our work on a novel drug-loaded hydrogel formulation in which we are repurposing pirfenidone - a drug currently approved for treating idiopathic pulmonary fibrosis, for urological applications, specifically targeting the fibrotic mechanisms underlying urethral stricture. Together, this work provides both a clinically relevant disease-model platform and an innovative local drug-delivery system with significant potential to transform how we understand and treat urethral stricture disease.

Receiving the SBUR Travel Award was a truly transformative milestone in my journey as a graduate researcher. As a joint PhD student between the Indian Institute of Technology Madras (IITM) and the University of California San Diego (UCSD), attending a prestigious conference of this caliber would not have been possible without this generous support, and I am deeply grateful to SBUR for recognizing our work. The SBUR Fall Meeting 2025 offered me an extraordinary window into the full translational pipeline of urological research, from early-stage laboratory discoveries to how novel therapies are developed, tested, and ultimately delivered to patients. Engaging with leading researchers, clinicians, and innovators gave me an invaluable perspective on best practices in research and the evolving landscape of urology. I look forward to continuing to contribute to this remarkable community at future conferences.



Huan Qu, PhD, University of California Davis, Travel Awardee

My poster presented a novel RNA-based therapeutic strategy for treatment-resistant prostate cancer by targeting the previously "undruggable" receptor PLXND1. Using a bioengineered siRNA platform and lipid nanoparticle delivery, we demonstrated effective gene silencing and tumor growth inhibition in preclinical prostate cancer models.

Attending the SBUR Fall Meeting allowed me to present my research, receive feedback from experts, and connect with investigators across institutions. Receiving the Travel Award was a meaningful recognition of my work and further motivated my pursuit of prostate cancer research.



Livia M. Bogdan, Purdue University, Travel Awardee, selected for podium presentation

At SBUR, I had the pleasure of presenting my research through both an oral travel award talk and a poster presentation. This work, completed during my gap year in Dr. Ashley R. Jackson's lab, investigates the role of Notch signaling in renal urothelium differentiation during urinary tract obstruction.

SBUR was the first conference I have attended in my academic career and has been an invaluable entry point into the world of research. This summer, I will begin an MD/PhD program and look forward to carrying the insights I gained at SBUR into my development as a physician-scientist.



Nikhila Suresh, PhD, Purdue University, Eula and Donald S. Coffey Innovative Research Award finalist

A computational single-cell analysis workflow has been developed to identify inflammation-associated transitional epithelial states in benign prostatic hyperplasia (BPH). By integrating mouse and human prostate transcriptomic datasets, the study reveals conserved transitional cell populations and highlights androgen receptor signaling as a key pathway linking inflammation to epithelial remodeling, providing a foundation for future therapeutic targeting in prostate disease.

This SBUR Travel Award enabled me to present this computational work to leading investigators in urologic research and receive feedback from both experimental and clinical scientists. These discussions are essential for advancing integrative multi-omics approaches that translate large-scale molecular data into clinically relevant insights for urologic disease.



Xingbo Long, MD, Beth Israel Deaconess Medical Center, Travel Awardee, selected for podium presentation

My presentation explores how obesity may influence prostate growth and response to 5 α -reductase inhibitor therapy in benign prostatic hyperplasia. By integrating mouse single-cell RNA sequencing, human spatial transcriptomics, and clinical cohort data, our study suggests that obesity-associated metabolic changes may promote stem-like epithelial programs and contribute to variability in treatment response.

Receiving the SBUR Travel Award and attending the meeting provides a valuable opportunity to share my work, learn from leading researchers in the field, and receive helpful feedback that will guide my future research in prostate disease and translational urology.

Jaceline Sanches and Yaru Xu were also travel awardees but did not provide the requested materials.

FINANCE COMMITTEE UPDATE



Xin Lu, Ph.D.
SBUR Finance Committee Chair

I am pleased to report that the Society for Basic Urologic Research remains in a strong and healthy financial position. Thanks to your continued dedication through timely membership dues and active participation in our annual meetings and spring symposia, SBUR maintains a solid financial foundation. Our liquidity remains strong for daily operations, while our diversified investment portfolio, including the Leland Chung Endowment, Coffey Lectureship, and Young Investigator Award funds, continues to generate reliable long-term returns to support our mission. Furthermore, our ongoing revenue share partnership with the American Journal of Clinical and Experimental Urology (AJCEU) continues to provide a valuable supplementary stream of income, demonstrating the mutual benefits of our vibrant scientific community.

This financial stability allows us to directly invest back into our membership by expanding trainee travel awards, funding prestige lectureships, and delivering high-caliber programming at our conferences. Looking ahead, our committee is dedicated to ensuring sustainable financial stewardship that preserves SBUR's independence and supports our emerging scientific initiatives. We deeply appreciate your loyal support and encourage you to continue strengthening SBUR's financial health by renewing your membership, encouraging colleagues and trainees to join, submitting your quality research to AJCEU, and helping us connect with prospective industry partners and meeting sponsors. Thank you for your continued commitment to keeping SBUR vibrant and financially sound!

SBUR SUMMER 2026 TRAINEE WEBINAR SERIES

This was our second annual SBUR Summer Trainee Webinar Series. It was a fascinating and rewarding experience for all the participants. The speakers gave extremely informative and inspiring presentations. Many thanks to these talented trainees who shared their latest, brilliant research and to the attendees for the insightful discussions. We are deeply grateful for the commitment to basic urology research of all our rising SBUR stars! A brief (promise!) survey will be sent to all SBUR members for your feedback and ideas for next year's SBUR Summer 2027 Trainee webinar series.

Here are the presenters for this year's **SBUR SUMMER 2026 TRAINEE WEBINAR SERIES!**

Christina Jamieson, PhD
SBUR Immediate-Past President

Webinar #1: Prostate Disease • Friday, July 10th, 2026



TROP2 is a Biomarker and Therapeutic Target for Prostate Cancer

Diana Argiles-Castillo, PhD-Candidate in the Stoyanova Lab at UCLA

Diana has extensive oncology target and drug discovery experience. While working for several years, first at Dana-Farber Cancer Institute and then at Novartis, she developed high-throughput screening assays to profile drug-target interactions and advance therapeutic pipelines in oncology-based projects. At UCLA, she works on validating potential targets in advanced prostate cancer, particularly for their use as a biomarker and therapeutic target. During her talk, she told us about the Stoyanova Lab's current work on TROP2 as a biomarker for advanced prostate cancer and its therapeutic potential for antibody-based therapies.

Webinar #2: Bladder Disease • Friday, July 24th, 2026



Changes within the Tumor Microenvironment in Response to Novel Gene Therapy Agents

Dr. Taylor Alexandra Goodstein-Urology Fellow in Dr. Jindan Yu's laboratory

Dr. Taylor Goodstein is an incoming Assistant Professor of Urology at University of Cincinnati. She recently completed her Urologic Oncology fellowship at Emory Urology. During her fellowship, she conducted one year of dedicated translational research in novel therapeutics for non-muscle invasive bladder cancer, for which she received grant funding. She completed her residency at The Ohio State University in Columbus, Ohio. Before moving to Ohio for residency, she attended medical school in her home state of Colorado at the University of Colorado School of Medicine. Her clinical interests are mostly in bladder and kidney cancer. Other than her translational work in bladder cancer, she performs population-based outcomes research in kidney and prostate cancer and is committed to increasing resident involvement in scholarly pursuits.



Integrated Transcriptomic and Proteomic Analyses Identify Novel Biomarkers of Bladder Outlet Obstruction

Dr. Alex Bigger-Allen, PhD-Graduate student, now post-doctoral fellow in Dr. Rosalyn Adam's lab

Dr. Alex Bigger-Allen started doing biological research during the summer of his junior year at Wesleyan University. He was a research assistant at the New York State department of Health, where he worked with Dr. Valerie Bolivar providing image and behavioral analysis support on a mouse model of autism spectrum disorder. After graduating college, Dr. Bigger-Allen began working as a research assistant and lab manager for Drs. Patricia D'Amore and Joseph Arboleda-Velasquez at Schepens Eye Research Institute. There he supported research on a monogenic form of vascular dementia. Dr. Bigger-Allen received his Ph.D. in the Biology and Biomedical Science program at Harvard University where he contributed to work in Dr. Rosalyn Adam's Lab. He has continued working with Dr. Adam as a Post-doc focusing on identifying biomarkers of bladder obstruction.

Webinar #3: Other Urologic Diseases • Friday, August 21st, 2026



PSMA Expression in Germ Cell Tumors

Kemuel Clarke, BS-Post-bac student, Drs. Yasser Ged and Cathy Handy Marshall

Kemuel Clarke is a research assistant in the Genitourinary Oncology Department at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He is currently a post-baccalaureate fellow in the Schaufeld Program, where he is conducting cancer research before pursuing medical school. He earned his B.S. in Biology from Howard University and is interested in cancer research, health equity, and translating scientific discoveries into better patient care. Outside of research, he enjoys mentoring students, community engagement, and exploring new food and travel experiences.



An unconventional Uropathogen Usurps Host-derived Fatty Acids

Jamisha Francis, BS-Graduate student in Dr. Maria Hadjifrangiskou's lab

Jamisha Francis hails from St. Thomas, U.S. Virgin Islands. After earning her B.S. in Biology with a minor in Psychology from the University of the Virgin Islands, she transitioned to Vanderbilt University to begin her Ph.D. journey. Her scientific research delves into the complexities of the male and female urobiome. A scientist with a creative streak, Jamisha spends her free time working as a graphic designer, helping brands bring their visual identity and marketing to life.

ANNOUNCEMENTS

2026 SBUR Annual Meeting




SBUR

SOCIETY FOR BASIC UROLOGIC RESEARCH, INC.

ANNUAL MEETING
NOVEMBER 12-15

2026

Memphis Riverline Hotel by Marriott
MEMPHIS, TENNESSE

REGISTER NOW!

2027 SBUR Annual Meeting



ANNUAL MEETING



PORTLAND

Society of Basic Urologic Research, Inc.

SBUR  **2027**

NOVEMBER 11-14